• Corpus ID: 235755249

Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline

@article{MacMahon2021IdentificationAV,
  title={Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline},
  author={M{\'e}abh MacMahon and Woochang Hwang and Soorin Yim and Eoghan MacMahon and A Abraham and Justin Barton and Mukunthan Tharmakulasingam and Paul Bilokon and Vasanthi Priyadarshini Gaddi and Namshik Han},
  journal={ArXiv},
  year={2021},
  volume={abs/2107.02905}
}
SARS-CoV-2, the causative virus of COVID-19 continues to cause an ongoing global pandemic. Therapeutics are still needed to treat mild and severe COVID-19. Drug repurposing provides an opportunity to deploy drugs for COVID-19 more rapidly than developing novel therapeutics. Some existing drugs have shown promise for treating COVID-19 in clinical trials. This in silico study uses structural similarity to clinical trial drugs to identify two drugs with potential applications to treat early COVID… 

Figures from this paper

References

SHOWING 1-10 OF 47 REFERENCES

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

TLDR
A human–SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.

The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

TLDR
It can be hypothesized that the NF-κB, cytokine regulation, ERK, and TNF-α signaling pathways are the likely causes of inflammation at the onset of COVID-19, and several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways.

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

TLDR
The cellular infection profile of SARS-CoV-2 is revealed and the identification of drugs that inhibit viral replication is enabled, enabling the development of therapies for the treatment of COVID-19.

Cell entry mechanisms of SARS-CoV-2

TLDR
Key cell entry mechanisms of SARS-CoV-2 that potentially contribute to the immune evasion, cell infectivity, and wide spread of the virus are identified using biochemical and pseudovirus entry assays and the potency and evasiveness are highlighted.

Clinical management of COVID-19

TLDR
The evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings are reviewed.

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

TLDR
In the peripheral blood mononuclear cells of COVID-19 patients, the authors observed reduced expression of human leukocyte antigen class DR (HLA-DR) and proinflammatory cytokines by myeloid cells as well as impaired mammalian target of rapamycin (mTOR) signaling and interferon-α (IFN-α) production by plasmacytoid dendritic cells.

Drug repurposing: progress, challenges and recommendations

TLDR
Approaches used for drug repurposing (also known as drug repositioning) are presented, the challenges faced by the repurpose community are discussed, and innovative ways by which these challenges could be addressed are recommended to help realize the full potential of drugRepurposing.